See more : Innovative Eyewear, Inc. (LUCY) Income Statement Analysis – Financial Results
Complete financial analysis of Nanobiotix S.A. (NBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nanobiotix S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ClearVue Technologies Limited (CPV.AX) Income Statement Analysis – Financial Results
- The Ruby Mills Limited (RUBYMILLS.BO) Income Statement Analysis – Financial Results
- ABN AMRO Bank N.V. (ABMRF) Income Statement Analysis – Financial Results
- Kyoden Company, Limited (6881.T) Income Statement Analysis – Financial Results
- Aros Bostadsutveckling AB (publ) (AROS.ST) Income Statement Analysis – Financial Results
Nanobiotix S.A. (NBTX)
About Nanobiotix S.A.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.06M | 4.78M | 10.00K | 50.00K | 68.00K | 116.00K | 251.97K | 1.56M | 265.54K | 967.50K | 184.94K | 74.15K | 1.36M |
| Cost of Revenue | 0.00 | 985.00K | 0.00 | 0.00 | 0.00 | 0.00 | 345.59K | 436.31K | 359.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 30.06M | 3.79M | 10.00K | 50.00K | 68.00K | 116.00K | -93.62K | 1.12M | -94.07K | 967.50K | 184.94K | 74.15K | 1.36M |
| Gross Profit Ratio | 100.00% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | -37.16% | 72.00% | -35.42% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 38.40M | 32.64M | 30.38M | 24.33M | 30.41M | 20.89M | 16.34M | 16.92M | 13.90M | 8.08M | 6.03M | 4.31M | 5.21M |
| General & Administrative | 21.66M | 17.48M | 19.43M | 14.27M | 18.64M | 12.62M | 12.34M | 10.26M | 7.19M | 4.30M | 3.61M | 1.81M | 1.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.66M | 17.48M | 19.43M | 14.27M | 18.64M | 12.62M | 12.34M | 10.26M | 7.19M | 4.30M | 3.61M | 1.81M | 1.30M |
| Other Expenses | -3.22M | -3.41M | -2.64M | -2.07M | -2.20M | -3.33M | -337.89K | 160.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 56.84M | 46.70M | 47.18M | 36.53M | 46.85M | 30.18M | 25.52M | 23.41M | 17.41M | 10.59M | 8.36M | 5.23M | 5.23M |
| Cost & Expenses | 56.84M | 46.70M | 47.18M | 36.53M | 46.85M | 30.18M | 25.52M | 23.41M | 17.41M | 10.59M | 8.36M | 5.23M | 5.23M |
| Interest Income | 1.22M | 256.00K | 6.17M | 4.68M | 105.00K | 34.00K | 33.03K | 59.49K | 183.22K | 196.65K | 59.06K | 46.00 | 11.53K |
| Interest Expense | 7.98M | 5.84M | 590.00K | 333.00K | 4.79M | 847.00K | 108.37K | 102.20K | 59.52K | 55.73K | 24.57K | 77.01K | 30.77K |
| Depreciation & Amortization | 1.51M | 1.50M | 1.56M | 1.76M | 1.77M | 569.00K | 345.59K | 436.31K | 456.08K | 307.56K | 233.93K | 146.53K | 197.62K |
| EBITDA | -30.09M | -45.15M | -45.61M | -31.49M | -44.78M | -29.33M | -25.55M | -21.21M | -16.49M | -9.11M | -7.89M | -5.01M | -5.02M |
| EBITDA Ratio | -100.09% | -1,084.63% | -409,950.00% | -59,906.00% | -65,845.59% | -25,282.76% | -10,172.33% | -1,360.96% | -6,208.97% | -942.01% | -4,264.36% | -6,781.21% | -368.90% |
| Operating Income | -26.78M | -46.70M | -52.58M | -36.43M | -46.78M | -30.07M | -25.27M | -21.85M | -17.14M | -9.62M | -8.18M | -5.15M | -5.23M |
| Operating Income Ratio | -89.09% | -977.85% | -525,790.00% | -72,856.00% | -68,792.65% | -25,919.83% | -10,027.88% | -1,402.65% | -6,455.32% | -994.29% | -4,422.79% | -6,948.91% | -384.27% |
| Total Other Income/Expenses | -12.80M | -10.33M | 5.58M | 2.85M | -4.13M | -278.00K | -876.00K | 64.61K | 138.56K | 142.52K | 34.50K | -99.18K | -19.34K |
| Income Before Tax | -39.58M | -57.03M | -47.00M | -33.61M | -50.91M | -30.35M | -26.14M | -21.79M | -17.00M | -9.48M | -8.14M | -5.25M | -5.25M |
| Income Before Tax Ratio | -131.68% | -1,194.16% | -469,990.00% | -67,228.00% | -74,870.59% | -26,159.48% | -10,375.61% | -1,398.50% | -6,403.14% | -979.56% | -4,404.14% | -7,082.66% | -385.69% |
| Income Tax Expense | 120.00K | 10.00K | 5.00K | 9.00K | 3.00K | -449.00K | 20.00 | 90.43K | 37.58K | 79.27K | 22.91K | 78.89K | 30.67K |
| Net Income | -39.70M | -57.04M | -47.00M | -33.62M | -50.92M | -29.90M | -26.14M | -21.88M | -17.00M | -9.56M | -8.14M | -5.33M | -5.25M |
| Net Income Ratio | -132.08% | -1,194.37% | -470,040.00% | -67,246.00% | -74,875.00% | -25,772.41% | -10,375.62% | -1,404.31% | -6,403.14% | -987.75% | -4,404.14% | -7,189.05% | -385.69% |
| EPS | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| EPS Diluted | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| Weighted Avg Shares Out | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.62M | 17.43M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
| Weighted Avg Shares Out (Dil) | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.63M | 17.48M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results...
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
PARIS & CAMBRIDGE, Mass. & SHANGHAI, China & PRINCETON, N.J.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, and LianBio (Nasdaq: LIAN), a biotechnology...
Nanobiotix's (NBTX) CEO Laurent Levy on Q1 2022 Results - Earnings Call Transcript
Nanobiotix S.A. (NASDAQ:NBTX ) Q1 2022 Earnings Conference Call May 19, 2022 8:00 AM ET Company Participants Kate McNeil – Senior Vice President, Investor Relations Laurent Levy – Co-Founder and Chief Executive Officer Bart Van Rhijn – Chief Financial Officer...
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman...
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorPlace.
Nanobiotix S.A (NBTX) CEO Laurent Levy on Q4 2021 Results - Earnings Call Transcript
Nanobiotix S.A (NBTX) CEO Laurent Levy on Q4 2021 Results - Earnings Call Transcript
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX TO ANNOUNCE FULL YEAR 2021 FINANCIAL RESULTS ON MARCH 30, 2022.
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company's leadership will participate in...
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two oral presentations and three poster presentations...
NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanophysics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of preclinical findings with...
Source: https://incomestatements.info
Category: Stock Reports